All News
SLE Conference Preview: progress in biologics
The pharmacology treatment including biologics, cellular-based therapies, and Bi-specific T-cell Engager (BiTE) in systemic lupus erythematosus (SLE) is a rapidly expanding field of research that provides excitement and optimism to both the patients and the physicians.
Read Article
Abstract #0189: Rheumatologists are early adopters and high utilizers of #AI scribes.
📊 Adoption: 41%
🧑💻 Retention: 100%
💬 High utilizers (> 70% visits): 83%. The highest among IM subspecialties
🕒 AI scribes reduced EHR time across all measures.
@RheumNow #ACR25 https://t.co/TBurWUKhMl
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Ramiro et al. No significant differences seen between men and women in response to upadacitinib in AxSpA at week 14 or 52. Differs from data on TNFi/IL17i in this regard. Looks to me like men respond a bit quicker and better though... @RheumNow #ACR25 Abstr#589 https://t.co/2m7mrgcG0z
Richard Conway RichardPAConway ( View Tweet)
This retrospective cohort analysis by Dr. Lihi Eder et al showed that among patients with PsA, those w/ high dse activity & high 3VAS scores were assoc w/⬆️ risk of atrial tachyarrythmias.
Main message: PsA conveys ⬆️CV risk; inflamm control is key!
#ACR25 @RheumNow Abs0522 https://t.co/7sRM7K4V1c
sheila RHEUMarampa ( View Tweet)
In a nationally representative NHANES sample, inflammatory back pain (IBP) was not associated with HLA-B27 positivity or elevated CRP, regardless of IBP criteria used (e.g., Berlin 8a: OR 0.88, p=0.876). IBP alone may be insufficient for identifying axSpA-related immunogenetic or https://t.co/82NjVU171z
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
What can we learn from longitudinal peripheral blood multi-omic profiling in at-risk individuals?
50 RA converters vs. non converters from StopRA study
Decision tree showing highest risk for conversion to clinical RA in Individuals w/
-CCP3 ≥108 units
-T peripheral helpers https://t.co/jw53EB6tI6
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#0774
Multi-omic profiling of anti-CCP3+ “at-risk” individuals reveals Tph & cytotoxic CD8+ expansions, altered gene/chromatin profiles and predictive model (AUC 0.77) for RA conversion
PTPN22 locus accessibility & Tph ≥ 2.45% identify highest risk. @RheumNow #ACR25 https://t.co/JDSMkdmoGv
Mrinalini Dey DrMiniDey ( View Tweet)
Not just for salivary glands—lacrimal ultrasound helps too.
In early Sjögren’s, lacrimal + salivary US clearly distinguished SjD from sicca (AUC up to 0.97).
Noninvasive, reproducible, and highly diagnostic.
@RheumNow #ACR25 Abstract #0507
Jiha Lee JihaRheum ( View Tweet)
A new marker for stratification of ILD in dermatomyositis: Anti MDA5 antibodies!
Japanese study
MDA5 (201-300) positivity associated w/
Lower 6-month progression-free survival (43% vs. 74%)
Lower 5-year survival rates (34% vs. 66%)
Validation in other populations awaited https://t.co/IBiYyATer4
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Dr. Werth on the #SLE guidelines on tx of cutaneous LE:
🔅All patients should be on hydroxychloroquine unless with CI.
☝️Important! For SLE pts presenting with new-onset rashes, review/ask about medications; consider drug-induced SCLE.
#ACR25 @RheumNow https://t.co/ok5jAi7uO0
Links:
sheila RHEUMarampa ( View Tweet)
Getting down with Jack at the @RheumNow #ACR25 stand - come and say hello!
(and Ask Cush Anything - scan the QR code, and maybe end up on the podcast!) https://t.co/0u0boHIIR3
David Liew drdavidliew ( View Tweet)
#ACR25 In a rush and wondering which abstract to look out for pertaining to new update on Biologics in #SLE #lupus? Please find my article on conference preview @RheumNow
https://t.co/usIXPsj5bm https://t.co/4wmWvDyv83
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Come to our first #HealthLiteracy poster of #ACR25!
#0190
Cluster analysis >900 people with IA
Lowest health literacy cluster assoc w:
4× ⬆️anxiety/depression
2× ⬆️disease activity, vs highest HL
Higher HL assoc w older age & ⬆️comorbidities but fewer mental health Sx
@RheumNow https://t.co/iIRXaOl4qZ
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
How does cMRI change over time in cardiac EGPA?
Cheng et al. retrospectively reviewed:
- 11 EGPA pt with LGE on initial cMRI
Despite treatment:
- 10/11 persistent LGE on 2nd cMRI
- 4/4 on 3rd
- 2/2 on 4th
Unclear use as a monitor of tx response
@RheumNow #ACR25
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
#0773 Anti-MDA5 epitope mapping identifies key regions (aa 201-300, 601-700) linked to treatment resistance & poor prognosis in DM-ILD and even IIPs.
Epitope-specific antibodies could refine risk stratification & guide therapy in ILD beyond autoimmune disease. @RheumNow #ACR25 https://t.co/moRffVGZPn
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR25 Abstr#0772. Should we be worried of #SLE patients with low uPCR 0.25-0.49? Kidney biopsy in N=28 + poor prognostic (Non-White, active serology or active sediment)
- 71% had LN (No class IV or Mixed)
- 46% actionable LN
Cost-effectiveness data needed.
#ACRBest @RheumNow https://t.co/Bt3fuA3aJh
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Organ Specific Recommendations-ACR guidelines for Management of SLE by Dr Lisa Sammaritano. @RheumNow #ACR2025 https://t.co/ilKWG8CQbe
Dr M Nazibur Rahman, MD (Rheumatology) NaziburM ( View Tweet)
AI-enhanced MRI integrating STIR and T1-weighted MRI with BME data reflecting both inflammatory and structural changes, enabling the AI model to predict clinical diagnoses of axSpA with accuracy of 82%. Successfully identified axSpA patients who did not meet the ASAS criteria for https://t.co/dLlGj0ZFpj
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Join us at 5pm CST for Day 1 #ACR25 recap! https://t.co/EwZSiPhysF
Dr. John Cush RheumNow ( View Tweet)
Plenary session at #ACR25!
#0772 When should we biopsy in SLE?
In pts with uPCR 0.25-0.49 g/g + LN predictors, 69% already had LN (many Class III/V). Low C3/C4 were most important factors.
0.5 g/g cutoff may delay diagnosis and treatment. Time to rethink thresholds? @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
